CASTLE BIOSCIENCES Business Summary

Castle Biosciences Inc. (CSTL) is a commercial-stage molecular diagnostics company that generates revenue primarily through the sale of proprietary genomic tests designed to guide clinical decision-making. The company’s business model is centered on a high-growth diagnostic portfolio categorized into three primary segments: dermatology (DecisionDx-Melanoma, DecisionDx-SCC), gastroenterology (TissueCypher for Barrett’s esophagus), and mental health (IDgenetix for pharmacogenomics). Revenue is driven by high-margin test volumes, with 2025 preliminary results exceeding $340 million, supported by a specialized sales force and expanding Medicare coverage. In the competitive landscape, Castle Biosciences contends with major players such as Myriad Genetics, Veracyte, and Natera; however, it maintains a dominant market position in the skin cancer diagnostic niche by providing superior risk-stratification data that traditional staging methods lack. The company was founded in 2007 by Derek J. Maetzold, who continues to serve as President and CEO, bringing over 30 years of experience from leadership roles at Encysive Pharmaceuticals and Schering-Plough. The executive team includes Frank Stokes as Chief Financial Officer, a former investment banker at SVB Leerink, and Kristen Oelschlager as Chief Operating Officer, who has been with the firm since its early stages. Research and development efforts are led by Dr. Rebecca Critchley-Thorne, Vice President of R&D, who joined following the acquisition of Cernostics. Castle Biosciences is backed by a robust roster of institutional investors, including BlackRock, Vanguard Group, and State Street Corporation, and is overseen by a board chaired by Daniel M. Bradbury, the former CEO of Amylin Pharmaceuticals.